4/23
01:45 pm
knsa
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock.
Low
Report
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock.
4/23
10:06 am
knsa
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]
4/23
07:37 am
knsa
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution [Yahoo! Finance]
Medium
Report
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution [Yahoo! Finance]
4/23
07:30 am
knsa
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
Medium
Report
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
4/16
04:01 pm
knsa
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
Low
Report
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
4/2
11:07 pm
knsa
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock, up previously from $28.00.
Medium
Report
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock, up previously from $28.00.
4/2
07:39 am
knsa
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart [Yahoo! Finance]
Medium
Report
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart [Yahoo! Finance]
4/2
07:30 am
knsa
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
Medium
Report
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
3/1
06:20 pm
knsa
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) was upgraded by analysts at TheStreet from a "d+" rating to a "c" rating.
Medium
Report
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) was upgraded by analysts at TheStreet from a "d+" rating to a "c" rating.
3/1
12:03 pm
knsa
Does Kiniksa Pharmaceuticals, Ltd. (KNSA) Have the Potential to Rally 32.45% as Wall Street Analysts Expect? [Yahoo! Finance]
Low
Report
Does Kiniksa Pharmaceuticals, Ltd. (KNSA) Have the Potential to Rally 32.45% as Wall Street Analysts Expect? [Yahoo! Finance]
2/29
11:42 pm
knsa
Chief Medical Officer John Paolini Sells 10,156 Shares of Kiniksa Pharmaceuticals Ltd (KNSA) [Yahoo! Finance]
Low
Report
Chief Medical Officer John Paolini Sells 10,156 Shares of Kiniksa Pharmaceuticals Ltd (KNSA) [Yahoo! Finance]
2/29
01:54 pm
knsa
Are You Looking for a Top Momentum Pick? Why Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Great Choice [Yahoo! Finance]
Low
Report
Are You Looking for a Top Momentum Pick? Why Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Great Choice [Yahoo! Finance]
2/29
09:33 am
knsa
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/28
05:12 pm
knsa
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $28.00 price target on the stock.
Medium
Report
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $28.00 price target on the stock.
2/28
10:26 am
knsa
Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 Earnings and Revenues Surpass Estimates [Yahoo! Finance]
Low
Report
Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 Earnings and Revenues Surpass Estimates [Yahoo! Finance]
2/28
08:14 am
knsa
Kiniksa Pharmaceuticals Ltd (KNSA) Reports Strong Revenue Growth in Q4 and Full-Year 2023 [Yahoo! Finance]
Medium
Report
Kiniksa Pharmaceuticals Ltd (KNSA) Reports Strong Revenue Growth in Q4 and Full-Year 2023 [Yahoo! Finance]
2/28
07:48 am
knsa
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution [Yahoo! Finance]
Medium
Report
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution [Yahoo! Finance]
2/28
07:30 am
knsa
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
Medium
Report
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
2/21
04:01 pm
knsa
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
Low
Report
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
2/12
12:16 pm
knsa
Wall Street Analysts Predict a 38.07% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Here's What You Should Know [Yahoo! Finance]
Low
Report
Wall Street Analysts Predict a 38.07% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Here's What You Should Know [Yahoo! Finance]
2/12
10:09 am
knsa
Kiniksa Pharmaceuticals, Ltd. (KNSA) is on the Move, Here's Why the Trend Could be Sustainable [Yahoo! Finance]
Low
Report
Kiniksa Pharmaceuticals, Ltd. (KNSA) is on the Move, Here's Why the Trend Could be Sustainable [Yahoo! Finance]
1/31
08:59 am
knsa
GSK (GSK) Misses Q4 Earnings Estimates [Yahoo! Finance]
Medium
Report
GSK (GSK) Misses Q4 Earnings Estimates [Yahoo! Finance]